BidaskClub upgraded shares of Vital Therapies (NASDAQ:VTL) from a hold rating to a buy rating in a research note released on Saturday.
VTL has been the subject of several other reports. ValuEngine raised shares of Vital Therapies from a sell rating to a hold rating in a research note on Wednesday, May 2nd. Zacks Investment Research lowered shares of Vital Therapies from a hold rating to a sell rating in a research note on Saturday, March 17th. Finally, BTIG Research reaffirmed a hold rating on shares of Vital Therapies in a research note on Monday, May 28th. Two analysts have rated the stock with a hold rating and three have issued a buy rating to the company. Vital Therapies has an average rating of Buy.
Shares of VTL opened at $6.85 on Friday. Vital Therapies has a fifty-two week low of $2.42 and a fifty-two week high of $7.30.
Vital Therapies (NASDAQ:VTL) last posted its quarterly earnings data on Tuesday, May 8th. The company reported ($0.34) EPS for the quarter, hitting the consensus estimate of ($0.34). equities analysts expect that Vital Therapies will post -1.23 EPS for the current year.
Several institutional investors and hedge funds have recently modified their holdings of VTL. BlackRock Inc. boosted its stake in shares of Vital Therapies by 136.2% during the fourth quarter. BlackRock Inc. now owns 990,828 shares of the company’s stock valued at $5,896,000 after purchasing an additional 571,418 shares during the period. Millennium Management LLC boosted its stake in shares of Vital Therapies by 65.6% during the first quarter. Millennium Management LLC now owns 414,540 shares of the company’s stock valued at $2,819,000 after purchasing an additional 164,175 shares during the period. Artal Group S.A. boosted its stake in shares of Vital Therapies by 14.3% during the first quarter. Artal Group S.A. now owns 1,000,000 shares of the company’s stock valued at $6,800,000 after purchasing an additional 125,000 shares during the period. Chicago Capital LLC purchased a new stake in shares of Vital Therapies during the first quarter valued at $677,000. Finally, Tibra Equities Europe Ltd purchased a new stake in shares of Vital Therapies during the first quarter valued at $416,000. 28.15% of the stock is owned by hedge funds and other institutional investors.
About Vital Therapies
Vital Therapies, Inc, a biotherapeutic company, focuses on developing and commercializing a cell-based therapy for the treatment of acute forms of liver failure in the United States. Its product candidate is the ELAD system, an extracorporeal human allogeneic cellular liver therapy that is in Phase III clinical trials helps in enhancing the rates of survival in patients with acute forms of liver failure.
Receive News & Ratings for Vital Therapies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vital Therapies and related companies with MarketBeat.com's FREE daily email newsletter.